BIOMAT Database Logo BIOMAT Database Logo

Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-disubstituted ureas. 2004

Brent R Stranix, and Gilles Sauvé, and Abderrahim Bouzide, and Alexandre Coté, and Guy Sévigny, and Jocelyn Yelle, and Valérie Perron
Procyon Biopharma Inc., 1650 Trans-Canada Highway, Suite 200, Dorval, Quebec, Canada, H9P 1H7. bstranix@procyonbiopharma.com

A series of lysine sulfonamide analogues bearing a Nepsilon-benzylic ureas was synthesized using both solution-phase and solid-phase approaches. A novel synthetic route of Nalpha-(alkyl)-Nalpha-(sulfonamides)lysinol using alpha-amino-caprolactam was developed. Evaluation of these novel protease inhibitors revealed compounds with high potency against wild-type HIV virus.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008239 Lysine An essential amino acid. It is often added to animal feed. Enisyl,L-Lysine,Lysine Acetate,Lysine Hydrochloride,Acetate, Lysine,L Lysine
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013449 Sulfonamides A group of compounds that contain the structure SO2NH2. Sulfonamide,Sulfonamide Mixture,Sulfonamide Mixtures,Mixture, Sulfonamide,Mixtures, Sulfonamide
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV

Related Publications

Brent R Stranix, and Gilles Sauvé, and Abderrahim Bouzide, and Alexandre Coté, and Guy Sévigny, and Jocelyn Yelle, and Valérie Perron
Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-acyl aromatic alpha-amino acids.
July 2006, Bioorganic & medicinal chemistry letters,
Brent R Stranix, and Gilles Sauvé, and Abderrahim Bouzide, and Alexandre Coté, and Guy Sévigny, and Jocelyn Yelle, and Valérie Perron
Unsymmetrical cyclic ureas as HIV-1 protease inhibitors: novel biaryl indazoles as P2/P2' substituents.
November 1999, Bioorganic & medicinal chemistry letters,
Brent R Stranix, and Gilles Sauvé, and Abderrahim Bouzide, and Alexandre Coté, and Guy Sévigny, and Jocelyn Yelle, and Valérie Perron
Novel azacyclic ureas that are potent inhibitors of HIV-1 protease.
August 1996, Biochemical and biophysical research communications,
Brent R Stranix, and Gilles Sauvé, and Abderrahim Bouzide, and Alexandre Coté, and Guy Sévigny, and Jocelyn Yelle, and Valérie Perron
Two sulfonamides-containing dihydropyrone derivatives as HIV protease inhibitors.
July 2001, Archiv der Pharmazie,
Brent R Stranix, and Gilles Sauvé, and Abderrahim Bouzide, and Alexandre Coté, and Guy Sévigny, and Jocelyn Yelle, and Valérie Perron
Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors.
January 1994, Science (New York, N.Y.),
Brent R Stranix, and Gilles Sauvé, and Abderrahim Bouzide, and Alexandre Coté, and Guy Sévigny, and Jocelyn Yelle, and Valérie Perron
Tricyclic ureas: a new class of HIV-1 protease inhibitors.
December 1998, Bioorganic & medicinal chemistry letters,
Brent R Stranix, and Gilles Sauvé, and Abderrahim Bouzide, and Alexandre Coté, and Guy Sévigny, and Jocelyn Yelle, and Valérie Perron
The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitors.
May 1998, Bioorganic & medicinal chemistry letters,
Brent R Stranix, and Gilles Sauvé, and Abderrahim Bouzide, and Alexandre Coté, and Guy Sévigny, and Jocelyn Yelle, and Valérie Perron
Disubstituted Bis-THF Moieties as New P2 Ligands in Nonpeptidal HIV-1 Protease Inhibitors.
June 2011, ACS medicinal chemistry letters,
Brent R Stranix, and Gilles Sauvé, and Abderrahim Bouzide, and Alexandre Coté, and Guy Sévigny, and Jocelyn Yelle, and Valérie Perron
4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors.
September 2011, Bioorganic & medicinal chemistry letters,
Brent R Stranix, and Gilles Sauvé, and Abderrahim Bouzide, and Alexandre Coté, and Guy Sévigny, and Jocelyn Yelle, and Valérie Perron
Aging increases Nepsilon-(carboxymethyl)lysine and caloric restriction decreases Nepsilon-(carboxyethyl)lysine and Nepsilon-(malondialdehyde)lysine in rat heart mitochondrial proteins.
January 2002, Free radical research,
Copied contents to your clipboard!